logo
NHS waiting lists: Working age people a growing proportion of those needing help

NHS waiting lists: Working age people a growing proportion of those needing help

Yahoo17-07-2025
People of working age are making up a growing proportion of those on the NHS waiting list for treatment in England, according to analysis.
Data tables published for the first time by NHS England also show people in the most deprived parts of the country are more likely to wait more than a year to start hospital treatment than those in the least deprived.
The figures, analysed by the PA news agency, show 56.1% of those on the list at the end of June this year were of working age (defined as age 19 to 64), up from 55.8% a year ago and 55.0% in June 2022.
At the same time, the proportion of people on the waiting list under the age of 19 has fallen, standing at 10.8% in June this year, down from 11.2% a year earlier and 11.9% in June 2022.
The proportion who are over 65 has remained broadly unchanged at around 33.1%.
People of working age are also more likely to have to wait more than a year to start treatment (3.0% of patients in this age group at the end of June) than those over 65 (2.5%).
However, the proportion is the same as those under 19 (also 3.0%).
Meanwhile, people in the most deprived parts of England also face long waits for treatment when compared with those in the wealthiest areas.
And for data where sex is recorded, women make up a higher percentage of the waiting list (57%) compared with men (43%).
Women are also more likely to be waiting more than 18 and 52 weeks than men.
On deprivation, some 3.1% of patients living in the most deprived areas had been waiting more than 12 months to begin treatment at the end of June, compared with 2.7% in the least deprived.
The gap is even wider in some regions, with the figures for the Midlands ranging from 3.0% in the most deprived parts to 2.4% in the least deprived; from 2.4% to 1.8% in London; and from 4.9% to 4.0% in eastern England.
The data also shows patients in certain ethnic groups are more likely to have to wait more than a year to start hospital treatment than in others.
Some 3.2% of patients in England identifying as Bangladeshi had been waiting more than 12 months to begin treatment at the end of June, along with 3.0% of patients of Pakistani and African backgrounds, higher proportions than those identifying as Caribbean (2.9%), Chinese (2.8%), British (2.8%) or Indian (2.7%).
Eastern England and south-west England are the regions with the largest ethnicity gap for people waiting more than a year to begin hospital treatment.
The Government has announced new neighbourhood health centres in its 10-year plan for the NHS, which will be targeted first at the places where healthy life expectancy is lowest.
According to the Department of Health, this includes 'de-industrialised cities and coastal towns, reducing the estimated £240-£330 billion cost of sickness to the economy.'
Some 20 'further faster' teams have also been sent in to those NHS trusts with the longest waits to try to bring them down.
The new data shows the largest specialty for those on the waiting list aged 18-64 is gynaecology (12% of all 18 to 64-year-olds), while it is ophthalmology for older adults.
Health and Social Care Secretary, Wes Streeting, said: 'We inherited an NHS which after years of neglect had left all patients worse off – but some more than others.
'Sunlight is the best disinfectant. Only by being upfront and shining a light on inequalities can we begin to tackle the problem.
'We will give all patients the care they need when they need it as part of our Plan for Change.
'Our 10-Year Health Plan will tackle health inequalities faced across the country, diverting billions of pounds to working-class communities, and providing truly targeted, bespoke care to all patients where they live via the neighbourhood health service.'
Stella Vig, NHS national clinical director for elective care, said: 'Understanding patient demographics is vital if we are to identify and tackle the way different groups are treated.
'As well as allowing patients and the public to see the makeup of local lists, NHS teams will be able to analyse the latest data, understand where there is unwarranted variation in waiting times, and work with their communities to take action to reduce it.'
Professor Habib Naqvi, chief executive of the NHS Race and Health Observatory, said: 'This is a great step in making ethnic health inequities more visible.
'Without robust, consistent data and transparency about what's happening in the healthcare system, we will not be able to enable genuine equitable decision making in the NHS, nor tackle and eradicate ethnic and racial inequalities in health in a sustained and meaningful way.'
It comes as the Government announced that patients with long-term conditions will be automatically referred to specialist charities at the point of diagnosis from next year.
Diagnosis Connect will ensure patients are referred directly to charities and support organisations in a move the Government says will 'complement, not replace', NHS care.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

LucyRx Announces the Acquisition of CerpassRx, Enhancing Clinical Excellence and Expanding Access to Innovative Healthcare Solutions
LucyRx Announces the Acquisition of CerpassRx, Enhancing Clinical Excellence and Expanding Access to Innovative Healthcare Solutions

Yahoo

time6 minutes ago

  • Yahoo

LucyRx Announces the Acquisition of CerpassRx, Enhancing Clinical Excellence and Expanding Access to Innovative Healthcare Solutions

This strategic move brings together industry leading service with modern, member-first prescription care. BETHESDA, Md., July 31, 2025--(BUSINESS WIRE)--LucyRx, a fast-scaling, next-generation pharmacy benefits manager (PBM) known for simplifying and improving access to prescription care, has signed a definitive agreement to bring CerpassRx into the LucyRx organization. The combination brings together CerpassRx's proven track record of exceptional service and cost containment with LucyRx's technology-driven clinical approach, all under a shared vision for smarter, more transparent prescription care. CerpassRx is a division of Nomi Health, a direct healthcare company. The transaction is subject to regulatory approvals and customary closing conditions and is expected to close in Q3 2025. By combining LucyRx's technology-driven clinical model with CerpassRx's service-first approach and cost containment expertise, this partnership creates a more impactful PBM solution - one that delivers smarter care, stronger savings, and a seamless experience for clients and members alike. Distinct Strengths. Shared Mission. Greater Value. LucyRx and CerpassRx bring distinct but highly complementary capabilities to this new chapter. LucyRx offers a proprietary Formulary Marketplace, a broad Connected Specialty Care Network that integrates leading health systems and specialty pharmacies, and personalized clinical guidance through its Care Guide model. Its clinical programs focused on high-impact areas like GLP-1 therapies and Women's Health deliver smarter, more proactive prescription care for members. CerpassRx excels in driving down prescription costs through proprietary cost containment strategies, flexible formulary design, and tailored clinical programs. With a high-touch service model, it delivers rapid implementation and measurable outcomes, earning a reputation for disrupting the traditional PBM model and building long-term trust with clients and members. Together, they form a national PBM platform that is performance-driven, clinically forward, and relentlessly focused on serving clients and members with clarity and accountability. A More Impactful Platform for Clients and Members Smarter Cost Containment: CerpassRx's proven cost-saving programs layered onto LucyRx's transparent pricing and formulary marketplace. Stronger Member Support: Integrated clinical teams, anchored by LucyRx's Care Guides and CerpassRx's personalized service culture. Scalable Innovation: LucyRx's AI-powered insights and infrastructure amplify CerpassRx's high-touch service, making care more personal at scale. "CerpassRx is a strong cultural and strategic fit for LucyRx," said David Blair, CEO of LucyRx. "We're combining two organizations who are relentlessly focused on performance, innovation and compassion, and continually raising the bar for what clients and members can expect from a PBM." "We're proud of the foundation CerpassRx has built, and we believe LucyRx is the right partner to take it even further," said Mark Newman, CEO and Co-Founder of Nomi Health. "This agreement reflects a shared vision for more transparent, tech-forward pharmacy care and we're confident it will create long-term value for clients, members, and the broader market." "Clients expect more from their PBM, and they should," said Susan Thomas, Chief Commercial Officer at LucyRx. "Together with CerpassRx, we expand both the reach and depth of our solutions. And we'll deliver an experience that is more personal, more affordable and more clinically impactful." "Joining LucyRx is a natural next step for our clients and our team," said John Nicolosi, PharmD, Interim President of CerpassRx. "Our shared values of clarity, accountability, and care make this a powerful combination. We're excited to extend our impact with the support of LucyRx's technology, scale, and clinical approach." What Clients and Members Can Expect There will be no changes to service, support, or operations as a result of this agreement. Clients and members will continue to receive the same high-quality care and responsiveness they've come to expect from both organizations. This move builds on LucyRx's momentum as a PBM committed to doing things differently, with an emphasis on clarity, clinical rigor, and measurable outcomes. As part of this agreement, Nomi Health and LucyRx will continue working together to support their shared clients and build on current partnership efforts to reduce pharmacy costs for both employers and their members, advancing a shared commitment to bring more transparency, innovation, and affordability to healthcare. About LucyRx LucyRx is fast-scaling, independent, next-generation pharmacy benefit manager (PBM) redefining prescription care. Fueled by innovation and decades of leadership experience, LucyRx delivers better outcomes through its integrated specialty network, formulary marketplace, and next-day home delivery solutions. Powered by its proprietary AI platform, LucyIQ™, the company provides real-time insights that support evidence-based clinical decisions, clear pricing, and exceptional service from U.S.-based pharmacy technicians. Partnering with more than 60,000 pharmacies, LucyRx serves over 1,200 clients nationwide. This is prescription care, brilliantly reimagined. Learn more at About CerpassRx CerpassRx is a leading, full-service, pharmacy benefit manager based in Dallas-Fort Worth, Texas. Its services include prescription optimization, flexible formulary designs, personalized member support, and efficient mail and specialty pharmacy programs. Committed to driving efficiency and enhancing pharmacy benefit management, CerpassRx helps clients navigate the complexities of prescription care. For more information, visit About Nomi Health Nomi Health is rebuilding healthcare through its direct model. Founded in 2019, the company's integrated platform combines analytics, direct provider networks, and real-time payment solutions - providing the infrastructure that powers better healthcare. The company serves 4,000 customers nationwide, impacting 30 million lives and influencing over $200 billion in healthcare spend. Based in Orem, Utah, Nomi Health leads the movement to rebuild America's healthcare system. Learn more at View source version on Contacts Media Contact for LucyRx Tricia Bancroft516-241-6157press@ Strategic Partnerships Contact at LucyRx Alex Motola, Chief Business Officer and Head of M&Aamotola@ Media Contact for Nomi Health Rebeca Damico385-887-1641rebeca@ Sign in to access your portfolio

Musk's Neuralink to test brain chips in clinical study in Great Britain
Musk's Neuralink to test brain chips in clinical study in Great Britain

Yahoo

time6 minutes ago

  • Yahoo

Musk's Neuralink to test brain chips in clinical study in Great Britain

(Reuters) - Elon Musk's brain implant company Neuralink said on Thursday it will launch a clinical study in Great Britain to test how its chips can enable patients with severe paralysis to control digital and physical tools with their thoughts. The company is partnering with the University College London Hospitals trust and Newcastle Hospitals to conduct the study, it said in a post on X. Neuralink said patients living with paralysis due to conditions such as spinal cord injury and a nervous system disease called Amyotrophic Lateral Sclerosis (ALS) qualify to participate in the study. The company raised $650 million in its latest funding round last month. It began human trials in 2024 on its brain implant after resolving safety concerns flagged by the U.S. Food and Drug Administration, which had initially rejected Neuralink's application in 2022. According to the company, five patients with severe paralysis are currently using its device to control digital and physical tools with their thoughts. Neuralink, founded in 2016, has raised about $1.3 billion from investors and is valued at roughly $9 billion, according to media reports, citing PitchBook.

ImmunityBio, Inc. (IBRX) Gains UK Approval for ANKTIVA in Bladder Cancer
ImmunityBio, Inc. (IBRX) Gains UK Approval for ANKTIVA in Bladder Cancer

Yahoo

time6 minutes ago

  • Yahoo

ImmunityBio, Inc. (IBRX) Gains UK Approval for ANKTIVA in Bladder Cancer

We recently compiled a list of ImmunityBio, Inc. stands eleventh on our list. ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best future stocks to buy now. It is transforming cancer care through immunotherapies that activate the body's natural defenses. Its lead therapy, ANKTIVA (nogapendekin alfa inbakicept), has already been approved by the FDA for treating certain types of bladder cancer. The company is now expanding its approach with a focus on reversing lymphopenia, an immune deficiency often caused by chemotherapy, radiation, or immunotherapy. In June 2025, the FDA authorized an Expanded Access Program for ANKTIVA under the Cancer BioShield platform, making it the first approved therapy to target treatment-induced lymphopenia in patients with solid tumors who failed standard therapies. At ASCO 2025, data showed that restoring immune health with ANKTIVA, especially when paired with CAR-NK therapy, can significantly improve survival in metastatic pancreatic cancer patients. Internationally, ImmunityBio, Inc. (NASDAQ:IBRX) is gaining momentum. In July 2025, the UK approved ANKTIVA with BCG for non-muscle invasive bladder cancer (NMIBC), marking its first approval outside the U.S. Additionally, a partnership with Saudi Arabia's health system will bring the Cancer BioShield platform to the Middle East. The company is also expanding clinical trials, including a U.S.-based study testing ANKTIVA with PD-1 inhibitors in non-small cell lung cancer (NSCLC), with plans to expand globally. Meanwhile, the business is seeking broader FDA approval for ANKTIVA + BCG in bladder cancer after addressing regulatory hurdles. A laboratory technician using high tech equipment to sequence cancer genomics. By targeting immune collapse caused by cancer treatments, ImmunityBio, Inc. (NASDAQ:IBRX) is introducing a paradigm shift, fighting both cancer and immune dysfunction simultaneously. With FDA designations, strategic global alliances, and promising clinical data, the company is advancing a potentially life-extending new standard in oncology. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store